“…ABVD (doxorubicin [adriamycin), bleomycin, vinblastine, dacarbazine) was the first-line treatment in 1248 (94%) patients. Among those who received ABVD, patients with limited disease received a median of four cycles (2-6), patients with intermediate disease a median of four cycles (2-8), and patients with advanced disease a median of six cycles(1)(2)(3)(4)(5)(6)(7)(8). The median duration of each cycle was 27 days.…”